Search results for: HTA
Filter search results
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of…
New Findings: Public Attitudes Towards End-of-Life Treatment in England and Wales
7 December 2012
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the…
New Research by OHE and University of Glasgow on cost of QALYs in Scotland
17 December 2012
New health care technologies often improve health but also increase costs. Judging whether they are good value for money involves comparing what QALYs are gained from new technologies, compared to…
Spotlight on OHE: Measurement and Valuation of Health Using PROMs
20 December 2012
The OHE continues to play a central role in the development and use of patient-reported outcomes measures (PROMs). The last quarter of 2012 was characteristically busy. The OHE continues to…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
The OHE has been very active in conceptualising approaches incorporating a broader assessment of the elements of value (often called “value based pricing” or “VBP”), as its publications to date…
New Pilot Study: Capturing Public Preferences about Health Care Priorities
16 January 2013
The proposals from the UK Department of Health (DH) for value based pricing (VBP) include a process whereby higher prices would be granted to medicines that tackle the most burdensome…
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
Jon Sussex presents on the opportunity costs of implementing NICE decisions in Wales, and OHE attend HESG in Leeds, January 2015. Opportunity costs of implementing NICE decisions in NHS Wales…
OHE Welcomes Dr. Aslam Anis
28 January 2015
Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015….
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
10 March 2015
Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value framework”. Payers in the…